![]() In October 2015, Praxbind (idarucizumab) by Boehringer Ingelheim Pharmaceuticals was approved as an anticoagulant reversal drug indicated for patients treated with Pradaxa (dabigatran) during emergency surgery or uncontrolled or life-threatening bleeding. The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period. The global anticoagulant reversal drugs market size is expected to reach USD 1.81 billion by 2027 and is expected to expand at a CAGR of 14.3% from 2020 to 2027 DUBLIN-( BUSINESS WIRE)-The "Global Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report by Product Type, Distribution Channel, and Segment Forecasts, 2020-2027" report has been added to 's offering.
0 Comments
Leave a Reply. |